The mission of the Alzheimer’s Drug Discovery Foundation is to rapidly accelerate the discovery of drugs to prevent, treat and cure Alzheimer’s disease. Through the tremendous support of donors, the ADDF has awarded more than $209 million to fund over 690 Alzheimer’s drug discovery programs, biomarker programs, and clinical trials in 19 countries. The ADDF focuses on translating the knowledge that has been gained about the causes of Alzheimer’s disease into drugs to conquer it. The ADDF supports an underfunded area—preclinical drug discovery and early-stage clinical trials of potential drug targets—that is often called the “valley of death” because it is where good ideas go to die.